evipedia.ai
← Back

Oxiracetam for Health & Longevity

Evidence Review created on 10/31/2026 using AI4L / Opus 5.5

Also known as: Hydroxypiracetam, ISF 2522, CGP 21690E, CT-848, 4-hydroxy-2-oxopyrrolidine-1-acetamide, Neuromet, Neuractiv, Neuromed, Neuracetam, Neuoxitam, Neuropia

Motivation

Oxiracetam is a synthetic compound developed in Italy in the 1970s as a memory-enhancing drug. It is a close chemical relative of piracetam, the first drug marketed for that purpose. It is thought to work by strengthening signaling between nerve cells in the brain regions that handle learning and memory. Its appeal lies in the prospect of keeping memory, attention and mental speed sharp as the brain ages.

For decades it was prescribed in parts of Europe and Asia for memory problems in older adults, including people with early dementia or cognitive complaints after a stroke, and in China it is also given into a vein after head injuries. Outside medical settings, it is sold online as a “smart drug” to healthy people hoping for sharper thinking, usually without a prescription or any assurance of product quality.

This review examines the human, animal and laboratory evidence on oxiracetam’s effects on thinking and brain health, its side effects and drug interactions, its legal status, and the practical questions that arise for health-conscious adults interested in protecting cognitive function over a long lifespan.

Benefits - Risks - Protocol - Conclusion

Four items give a high-level overview of oxiracetam’s pharmacology and clinical trial record.

Only four items are listed: the other oxiracetam publications found are narrow laboratory, pharmacokinetic or product-testing studies rather than overviews.

No relevant oxiracetam content was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io; oxiracetam is an unapproved drug in the United States (Cohen 2021) that these platforms have not covered. Andrew Huberman names oxiracetam only in passing, claiming racetams act by raising blood glucose and not recommending them (Huberman Lab episode), too briefly to serve as an overview.

Grokipedia

Oxiracetam

An encyclopedic summary of oxiracetam’s approved and investigational uses, adverse effects, pharmacology, chemistry, development history and legal status; useful orientation, but its mechanistic claims rest largely on animal work.

Examine

Oxiracetam benefits, dosage, and side effects

Summarizes six human trials (499 participants), grades evidence for slowing cognitive decline, notes the null Alzheimer’s trial, finds no evidence of enhancement in young unimpaired people, and gives typical supplement doses.

ConsumerLab

No ConsumerLab article on oxiracetam exists. ConsumerLab does not typically cover drugs that are unapproved in the United States.

Systematic Reviews

Five systematic reviews and meta-analyses that evaluate oxiracetam, alone or among other drugs, are listed below; three also pool its adverse events.

Mechanism of Action

Oxiracetam is a hydroxylated relative of piracetam. No single receptor target has been identified; proposed mechanisms come from animal and cell studies:

  • Glutamate receptor modulation: it increased the response of AMPA receptors (receptors for glutamate, the main excitatory neurotransmitter) in cultured neurons (Copani 1992) and slowed their desensitization in a study that also improved memory in Alzheimer-model mice (Guo 2026).
  • Synaptic strengthening: in slices of rat hippocampus (the brain’s memory hub) it produced a lasting rise in excitatory transmission resembling LTP (long-term potentiation, the strengthening of synapses that underlies memory) (Pugliese 1990).
  • Cholinergic (acetylcholine-related) and signaling effects: it prevented electroshock-induced falls in brain acetylcholine in rats (Spignoli 1986) and raised hippocampal PKC (protein kinase C, a signaling enzyme in memory formation) in learning-impaired mice (Fordyce 1995).
  • Competing view: a major review found no affinity for any major neurotransmitter receptor and no generally accepted mechanism (Gouliaev 1994).

Pharmacology: oral bioavailability (the share of a dose reaching the bloodstream) is 56–75% (Perucca 1984; Gschwind 1992, Ciba-Geigy authors). It is not metabolized; most leaves unchanged in urine, so CYP (cytochrome P450, the main drug-metabolizing liver enzymes) pathways are not involved (Perucca 1987). Half-life is about 8 hours in younger and 12 hours in older adults (Lecaillon 1990, Ciba-Geigy authors). In rats it concentrates in kidney, liver, lung and skin, with low brain uptake (Gschwind 1992); human spinal fluid levels reach 4–5% of blood levels (Parnetti 1990). The (S)-enantiomer (one mirror-image form) is the likely active form (Li 2017).

Historical Context & Evolution

Oxiracetam was developed by the Italian company ISF under the code ISF 2522 (Saletu 1985) and developed further by Ciba-Geigy as CGP 21690E (Hjorther 1987; Baumel 1989, Ciba-Geigy authors). Its intended use was treating memory and attention deficits in dementia and “organic brain syndrome” (mental decline caused by physical brain disease) of later life.

Through the early 1990s, placebo-controlled trials in Italy reported better cognitive test scores over 12 weeks (Villardita 1987; Maina 1989), while trials in Denmark, the Netherlands and the United States found no effect in solvent-induced brain syndrome, epilepsy-related memory problems and Alzheimer’s disease (Hjorther 1987; Aldenkamp 1990; Green 1992). Oxiracetam never gained approval in the United States (Cohen 2021) and, per a review, left Western clinical use (Malykh 2010).

It remained a reimbursed prescription drug in South Korea (Lim 2025) and is used in China after brain injury (Wang 2026). South Korea’s Ministry of Food and Drug Safety (MFDS) ordered a clinical re-evaluation; in January 2023 it advised switching to alternative drugs for vascular cognitive impairment because efficacy was not shown (MFDS 2023 drug information letter). The re-evaluation was framed around the cost of reimbursed legacy drugs, giving the payer a financial interest in delisting just as manufacturers had one in continued sales (Lim 2025).

Online “nootropic” (cognition-enhancer) communities later adopted it, citing animal memory data; the US Food and Drug Administration (FDA) has stated that oxiracetam is not a dietary supplement (FDA warning letter). Development now continues with the (S)-enantiomer in China (Zhang 2024).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the placebo-controlled oral trials in dementia are contested by null trials in Alzheimer’s disease and in post-stroke cognitive complaints, and the brain-injury data come from partly intravenous use.

Medium 🟩 🟩

Cognitive Test Scores in Impaired or Stressed Brains ⚠️ Conflicted

Placebo-controlled oral dementia trials reported better cognitive scores over 12 weeks (Villardita 1987; Maina 1989; Bottini 1992), as did amnesia and altitude challenges in healthy volunteers (Preda 1993; Hu 2017). A small Alzheimer’s trial (Green 1992) and a 500-person post-stroke trial (Lim 2025) found no benefit; an intravenous brain-injury trial sponsored by the L-oxiracetam ((S)-oxiracetam) developer did not compare racemic (mixed-form) oxiracetam with placebo (Liu 2025). The brain-injury figure below is indirect (partly intravenous). On balance, the consistent dementia trials outweigh null trials that mostly enrolled other populations.

Magnitude: After brain injury, a meta-analysis found MMSE 4.67 points higher than control (95% CI, the confidence interval likely to contain the true value, 3.07 to 6.28; 10 trials, 798 patients) (Wang 2026); after stroke, MMSE change +0.13 with oxiracetam versus +0.27 with placebo over 36 weeks (p = 0.49, p being the probability of a difference this large arising by chance) (Lim 2025).

Low 🟩

Neurological and Functional Recovery in Brain Injury and Vascular Cognitive Impairment ⚠️ Conflicted

Meta-analyses in brain injury (Wang 2026) and vascular cognitive impairment (Yi 2020) found higher Barthel Index (daily-activity independence) scores, and lower NIHSS (NIH Stroke Scale, a deficit score) after brain injury. An intravenous trial found similar scores, uncompared (Liu 2025). Indirect: partly intravenous, low certainty. Net, functional benefit is unconfirmed.

Magnitude: NIHSS 3.22 points lower than control (95% CI −4.14 to −2.30; 8 trials, 685 patients) (Wang 2026); Barthel Index 18 points higher than placebo or other drugs in vascular cognitive impairment (Yi 2020); 90-day Barthel daily-activity score 98.16 with oxiracetam versus 98.58 with placebo, not compared between groups (Liu 2025).

Speculative 🟨

Neuroprotection Against Neurodegeneration

Oxiracetam reduced hippocampal neuron loss in Alzheimer-model mice (Guo 2026) and calmed amyloid-triggered (Alzheimer’s plaque protein) microglia (brain immune cells) in culture (Zhang 2020). Evidence is laboratory and animal only.

Healthy Lifespan Extension

No study in any organism has measured lifespan or aging biomarkers with oxiracetam. Any longevity benefit is inferred solely from proposed brain-protective mechanisms.

Benefit-Modifying Factors

  • Genetic polymorphisms: no pharmacogenetic data exist; because oxiracetam is excreted unchanged rather than metabolized by liver enzymes, common enzyme variants are not expected to alter its exposure (Perucca 1987).
  • Baseline cognitive status: the null post-stroke trial enrolled people with near-normal MMSE (mean 26.6), leaving little room to improve; earlier positive dementia trials enrolled MMSE 11–24 (Villardita 1987; Lim 2025).
  • Kidney function: lower kidney clearance raises blood levels (Lecaillon 1990, Ciba-Geigy authors); whether higher exposure changes benefit is untested.
  • Sex: in the developer-funded brain-injury trial, L-oxiracetam improved cognitive scores in men but not women (interaction p = 0.038) (Liu 2025); racemic oxiracetam has not been analyzed by sex, and women were about a quarter of the post-stroke trial.
  • Pre-existing conditions: positive signals cluster in dementia and acute brain injury; trials in memory-impaired people with epilepsy (Aldenkamp 1990) and solvent-induced brain syndrome (Hjorther 1987) found no effect.
  • Age: older adults clear oxiracetam more slowly, roughly doubling exposure (Lecaillon 1990); no trial has tested cognitively healthy adults in mid-life or older age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been shown in excess of placebo in trials from more than one independent research group.

Medium 🟥 🟥

No risk reaches Medium: the only statistically significant excess came from a single high-dose intravenous trial, and label-listed reactions rest on uncontrolled post-marketing reports.

Low 🟥

Mild Gastrointestinal, Skin & General Adverse Events ⚠️ Conflicted

With intravenous oxiracetam 6 g/day for 14 days, treatment-related events, including gastrointestinal and skin reactions, exceeded placebo (Liu 2025); indirect: intravenous route, higher dose. With oral 800 mg twice daily, the excess was not significant (Lim 2025). Oral use carries at most a small excess of mild events.

Magnitude: Treatment-related adverse events 17.4% with intravenous oxiracetam versus 9.2% with placebo (three-group p = 0.049) (Liu 2025); any adverse event 41.0% with oral oxiracetam versus 34.9% with placebo (p = 0.16) (Lim 2025).

Overstimulation, Insomnia & Other Nervous-System Reactions ⚠️ Conflicted

China’s regulator added post-marketing reports of insomnia, irritability, excitation, confusion, headache, tremor and seizure-like episodes to oxiracetam labels (NMPA 2021 label revision notice). In an intravenous randomized trial, nervous-system events were not significantly more frequent than with placebo (Liu 2025). Net, these reactions are documented but unquantified.

Magnitude: Nervous-system adverse events 1.70% with intravenous oxiracetam versus 0.84% with placebo (three-group p = 0.129) (Liu 2025); the label reports come from spontaneous post-marketing surveillance with no comparison group.

Allergic-Type, Liver, Kidney, Heart-Rhythm & Respiratory Reactions ⚠️ Conflicted

China’s regulator added post-marketing reports of anaphylactoid (severe allergic-type) reactions, including injection-related anaphylactic shock, abnormal liver and kidney function, heart-rhythm disturbances and chest tightness or breathlessness to oxiracetam labels (NMPA 2021 label revision notice). An intravenous trial found no significant excess (Liu 2025). Net, these are rare, of unknown frequency.

Magnitude: Immune-system events 0.85% with intravenous oxiracetam versus 0% with placebo (three-group p = 0.358), heart, kidney and respiratory events each 0.42% versus 0%, and liver events 0% in both groups (Liu 2025); the label reports have no comparison group.

Speculative 🟨

Accumulation With Reduced Kidney Function

Oxiracetam is cleared unchanged by the kidneys; half-life reached 68 hours as creatinine clearance (kidney filtering) fell (Lecaillon 1990). No study has measured resulting harm; the basis is pharmacokinetic only.

Effects on Pregnancy

Radiolabeled oxiracetam crossed the placenta into fetal tissue in pregnant rats (Gschwind 1992). No human pregnancy or breastfeeding data exist; the concern rests on animal distribution data.

Risk-Modifying Factors

  • Genetic polymorphisms: none known; oxiracetam bypasses liver enzyme metabolism, so variants in CYP enzymes are not expected to change its levels (Perucca 1987).
  • Baseline kidney function: the single strongest modifier; half-life ranged from 10.6 to 68.1 hours across creatinine clearances of 95 down to 9 mL/min (Lecaillon 1990).
  • Sex: no sex-specific adverse-event analyses exist; women made up about a quarter of participants in the largest oral trial (Lim 2025), limiting safety data in women.
  • Pre-existing conditions: chronic kidney disease raises exposure; pregnancy is unstudied; people with mild-to-moderate dementia took 1,600 mg/day for up to 1 year without severe adverse events or laboratory changes (Villardita 1992).
  • Age: in older adults, exposure roughly doubled and half-life rose from 7.7 to 12.3 hours versus younger adults (Lecaillon 1990), reflecting age-related decline in kidney function.

Key Interactions & Contraindications

Documented interactions:

  • Antiepileptic drugs (seizure medications: carbamazepine, valproic acid): in people with epilepsy, co-use shortened oxiracetam’s half-life, requiring more frequent dosing; oxiracetam did not change antiepileptic blood levels (van Wieringen 1990); consequence: lower oxiracetam exposure, offset by split dosing.
  • Benzodiazepines (sedative-anxiolytic drugs: diazepam): in 12 volunteers given diazepam, intravenous oxiracetam 1 g shifted the EEG (electroencephalogram, a recording of brain electrical activity) toward alertness (Giaquinto 1986); consequence: possible partial offset of benzodiazepine effects. Cognitive outcomes were not measured.
  • Anticholinergic drugs (drugs that block acetylcholine: scopolamine): in healthy volunteers, oxiracetam reduced scopolamine-induced memory impairment, significantly only at 1,600 mg (Preda 1993); consequence: the two act in opposite directions, so each may blunt the other.
  • Food: for (S)-oxiracetam, food delayed peak blood levels to 3 hours without changing total exposure (Zhang 2024); consequence: slower onset when taken with meals. Data are for the enantiomer, not the racemic drug.
  • Physical activity: no interaction was found between oxiracetam and moderate-to-vigorous physical activity on cognitive outcomes (interaction p = 0.76) in 457 stroke survivors (Lim 2025).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Cholinesterase inhibitors (drugs that slow acetylcholine breakdown: donepezil, rivastigmine, galantamine): additive cholinergic activity inferred from oxiracetam’s acetylcholine effects in rats; consequence: possible nausea or headache. Starting one agent at a time separates their effects.
  • Other racetams (piracetam, aniracetam, phenylpiracetam): shared AMPA receptor modulation suggests additive excitatory effects; consequence: unpredictable overstimulation or insomnia. Avoiding combinations keeps effects attributable.
  • Stimulants (caffeine, modafinil, methylphenidate): additive central arousal inferred from excitatory glutamate signaling; consequence: insomnia or nervousness. Avoiding evening co-dosing limits sleep disruption.
  • NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen), regular use: reduced kidney blood flow inferred to slow clearance of a kidney-eliminated drug; consequence: higher oxiracetam levels. Kidney function checks matter with chronic NSAID use.
  • Over-the-counter anticholinergic antihistamines (diphenhydramine, doxylamine): opposing cholinergic activity, extrapolated from the scopolamine model; consequence: blunted oxiracetam effect and added next-day sedation.
  • Cholinergic supplements (alpha-GPC, i.e., alpha-glycerylphosphorylcholine; citicoline; huperzine A): additive cholinergic activity inferred from mechanism; consequence: possible headache or gastrointestinal upset. Adding one at a time keeps effects attributable.

Populations who should avoid Oxiracetam:

  • Severe kidney impairment: contraindicated on China’s oral oxiracetam label, which advises dose reduction in mild-to-moderate impairment (NMPA 2021 label revision notice); half-life reached 68 hours at creatinine clearance as low as 9 mL/min (Lecaillon 1990).
  • Pregnancy and breastfeeding: China’s label states oxiracetam should not be used because safety is not established (NMPA 2021 label revision notice); radiolabeled drug crossed the placenta into fetal tissue in rats (Gschwind 1992).
  • Hypersensitivity to oxiracetam: contraindicated on China’s oral label (NMPA 2021 label revision notice).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Kidney check before starting: serum creatinine and eGFR (estimated glomerular filtration rate, a calculated measure of kidney filtering capacity) identify reduced clearance, preventing unrecognized accumulation (Lecaillon 1990).
  • Lower dose with reduced kidney function or older age: halving to 800 mg/day offsets the roughly doubled exposure seen in older adults (Lecaillon 1990); no validated dose-adjustment table exists.
  • Start low: beginning at 800 mg/day for 1–2 weeks before the trial dose of 1,600 mg/day reveals gastrointestinal, skin or overstimulation effects early.
  • Morning and early-afternoon dosing: taking the last dose by mid-afternoon (a pharmacokinetic study used 8 a.m. and 2 p.m. (Perucca 1987)) limits possible insomnia.
  • Dose reduction for overstimulation: China’s label advises lowering the dose if excitation or sleep disturbance appears (NMPA 2021 label revision notice), limiting insomnia and agitation.
  • One new agent at a time: avoiding simultaneous starts with other racetams, stimulants or cholinergic supplements prevents additive overstimulation and keeps adverse effects attributable.
  • Verified product sourcing: independent certificates of analysis reduce the risk of undeclared drugs and wrong doses documented in racetam-labeled supplements (Cohen 2021).
  • Defined stopping point: reassessing at 12 weeks, the length of most trials, limits indefinite exposure to an unproven drug without measured benefit.
  • Avoidance in pregnancy: stopping before conception and during breastfeeding prevents fetal exposure, given placental transfer in rats (Gschwind 1992).

Therapeutic Protocol

Timing, titration and cycling parameters below that carry no citation reflect common practice.

  • Trial dose (oral): 800 mg twice daily (1,600 mg/day), the regimen in most placebo-controlled trials (Villardita 1987) and the approved Korean regimen (Lim 2025).
  • Supplement-community range: 1,200–2,400 mg/day in two or three doses (Examine oxiracetam page); 2,400 mg/day (800 mg three times daily) was used in trials (Aldenkamp 1990; Hu 2017).
  • Acute single dose: 800–2,400 mg about one hour before a demanding task; 1,600 mg was the effective dose in the scopolamine model (Preda 1993), and Examine describes pre-learning timing (Examine oxiracetam page).
  • Hospital intravenous use: 6 g/day by infusion for 14 days after brain injury in China (Liu 2025); not a self-administered regimen.
  • Who popularized it: no named longevity clinician publicly prescribes oxiracetam; consumer regimens derive from the Italian dementia trials and online nootropic communities, summarized by Examine (Examine oxiracetam page).
  • Time of day: morning and early afternoon, mirroring a pharmacokinetic study’s 8 a.m. and 2 p.m. schedule (Perucca 1987) and limiting evening stimulation.
  • Half-life: about 7.7 hours in younger and 12.3 hours in older adults (Lecaillon 1990); another study measured 3–6 hours in elderly women (Perucca 1987).
  • Single versus split dosing: split twice-daily dosing matches the half-life; 800 mg twice daily showed no accumulation over 7 days (Perucca 1987).
  • Genetic polymorphisms: none influence dosing, since oxiracetam is excreted unchanged without liver enzyme metabolism (Perucca 1987).
  • Sex: no sex-specific dosing exists; the only sex analysis found L-oxiracetam benefit in men but not women (Liu 2025).
  • Age: older adults reach about twice the exposure of younger adults (Lecaillon 1990), so a lower dose after 65 is common practice; no source gives an age-specific dose.
  • Baseline biomarkers: kidney function sets exposure; clearance falls in step with creatinine clearance (Lecaillon 1990), so dose reduction with lower eGFR is common practice.
  • Pre-existing conditions: positive trial signals came from dementia (Villardita 1987) and acute brain injury (a meta-analysis, Wang 2026), not healthy brains; epilepsy-related memory problems did not respond (Aldenkamp 1990).

Discontinuation & Cycling

  • Short-term, not lifelong: trials lasted 2 to 36 weeks, with one open-label extension to 1 year (Villardita 1992); no data support lifelong use.
  • Withdrawal effects: none have been reported, although no trial assessed them systematically after stopping.
  • Tapering: no tapering protocol exists or appears necessary, as oxiracetam has no known dependence mechanism; stopping at once is common practice.
  • Cycling: no evidence shows that cycling preserves efficacy or that tolerance develops; community on-off schedules have no supporting data.
  • Late changes on continued use: in the 1-year extension, some tests worsened versus baseline in the late phase (Villardita 1992), supporting periodic reassessment.

Sourcing and Quality

  • Regulatory gap: the FDA states oxiracetam is not a dietary supplement (FDA warning letter), so US products are sold outside both drug and supplement quality rules.
  • Label accuracy: in racetam-labeled supplements, oxiracetam was not among the drugs detected, undeclared aniracetam, phenibut and picamilon were found, and 9 of 12 declared quantities were inaccurate (Cohen 2021).
  • Pharmaceutical sources: Korean prescription products (Neuromed, Neuracetam, Neuoxitam, Neuropia; Dailypharm report) lost their recommended use in 2023 (MFDS 2023 drug information letter); oral and intravenous forms remain in Chinese hospital use (Wang 2026).
  • What to look for: a batch-specific certificate of analysis from an independent laboratory using HPLC (high-performance liquid chromatography, a purity assay), stating purity, related substances and whether the product is racemic or (S)-oxiracetam (Wang 2020).
  • Reputable brands: no consumer oxiracetam brand carries independent certification, and ConsumerLab has not tested oxiracetam products.
  • Formulation: sold as powder or capsules; the (S)-enantiomer is an investigational drug, not a consumer product (Zhang 2024).

Practical Considerations

  • Time to effect: acute effects appeared within hours in challenge models (Preda 1993); global improvement emerged within 1 week in one trial (Saletu 1985); dementia trials judged effects at about 12 weeks (Villardita 1987).
  • Common pitfalls: expecting enhancement in an unimpaired brain, combining several racetams and stimulants at once, trusting labels of unregulated products, and ignoring kidney function.
  • Regulatory status: not approved in the United States, and not a lawful dietary supplement per the FDA (FDA warning letter); South Korea’s regulator advised switching to alternatives in 2023 after efficacy was not shown (MFDS 2023 drug information letter).
  • Cost and accessibility: difficult to obtain legally from quality-controlled sources outside China; consumer supply comes mainly from online vendors selling unregulated products (Cohen 2021).
  • Placebo-sized changes: in the largest oral trial, 21% of placebo participants improved MMSE by 2 or more points (Lim 2025), so self-observed improvement is hard to attribute.

Interaction with Foundational Habits

  • Sleep: possible blunting; China’s label lists post-marketing insomnia and sleep disorder (NMPA 2021 label revision notice), though no trial measured sleep. Last dose by mid-afternoon is common practice; effects on sleep-deprived cognition remain untested at effective doses.
  • Nutrition: no direct interaction or nutrient depletion is known; food delays absorption of (S)-oxiracetam without reducing total exposure (Zhang 2024). Choline-rich foods (eggs, liver) are a theoretical cholinergic complement, untested.
  • Exercise: none found; physical activity did not modify oxiracetam’s effect (interaction p = 0.76), although the most active participants on oxiracetam showed a favorable exploratory trend (Lim 2025). Exercise was promoted in both groups, whose cognition stayed stable or improved.
  • Stress management: indirect and unquantified; older adults with brain syndrome showed within-group reductions in anxiety and emotional lability, not significant versus placebo (Saletu 1985); no data exist on cortisol or stress physiology.

Monitoring Protocol & Defining Success

Baseline testing before the first dose establishes kidney clearance and a personal cognitive reference point: serum creatinine with eGFR, and a standardized cognitive test such as the MoCA (Montreal Cognitive Assessment, a 30-point cognitive screening test) or a computerized battery, taken twice to absorb practice effects. A short diary of sleep quality, energy and mental clarity during the two weeks before starting gives a comparison for qualitative effects.

Ongoing monitoring follows this cadence: cognitive testing at 4 and 12 weeks, then every 6 months if use continues; creatinine and eGFR at 12 weeks, then every 6–12 months, and sooner after 65 or with regular NSAID use. Success is defined as a cognitive gain beyond practice effects at 12 weeks; without one, discontinuation is the usual endpoint in practice.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL (standard reference range) Safety check: kidney clearance sets oxiracetam exposure Fasting overnight and avoiding meat beforehand may be requested; interpreted together with eGFR; range from the Mayo Clinic creatinine test page
eGFR No established target; track change from own baseline Safety check: falling values lengthen half-life Calculated from creatinine, age and sex; values below 60 suggest kidney disease (Mayo Clinic creatinine test page); track change from own baseline; drug clearance tracks creatinine clearance (Lecaillon 1990)
Cognitive test score (MoCA or computerized battery) No established target; track change from own baseline Expected to change: the outcome oxiracetam aims to improve Same test version, time of day and caffeine status each time; placebo groups also improve (Lim 2025)

Qualitative markers:

  • Mental clarity and verbal fluency in daily tasks
  • Attention span during demanding work
  • Sleep onset and quality
  • Nervousness, headache or gastrointestinal upset
  • Energy and motivation

Emerging Research

  • No ongoing registered trials: a ClinicalTrials.gov search on 10/27/2026 found no recruiting or active oxiracetam trial, leaving the null 36-week post-stroke trial as the most recent large oral evidence (Lim 2025).
  • Brain-injury trial: L-oxiracetam versus oxiracetam versus placebo, phase 3, 590 randomized (NCT04205565); registry status “unknown”, completion date October 2024 passed; results published (Liu 2025): L-oxiracetam beat placebo on a cognitive battery; racemic oxiracetam gained 15.9 versus 11.5 points with placebo at 90 days, not compared between groups.
  • Healthy-adult racetam study: 70 adults aged 18–35, oxiracetam 100–300 mg/day among five compounds, phase 1 (NCT07852130); completed September 2026, no results posted; the registry states doses are too low to test efficacy, so neither result would change this review.
  • (S)-oxiracetam development: phase 1 studies show good tolerability, with exposure rising in proportion to dose after intravenous infusion (Liang 2021, developer co-authors) and oral doses up to 1,600 mg (Zhang 2024); efficacy trials of the active enantiomer could strengthen the case if positive or weaken it further if null.
  • Mechanism in Alzheimer models: AMPA receptor kinetics findings (Guo 2026) await human biomarker confirmation; failure to show target engagement in people would weaken the neuroprotection hypothesis.
  • Unanswered healthy-aging question: no placebo-controlled trial has tested oral oxiracetam for cognitive aging in healthy middle-aged adults; such a trial would directly address this review’s goal, in either direction.

Conclusion

Oxiracetam is a synthetic memory drug from the 1970s, a close relative of piracetam, now sold online as a cognitive enhancer and still used in Chinese hospitals after brain injury. For health-focused adults seeking to protect thinking over a long life, the evidence is weak and mixed.

Older, smaller trials in people with dementia reported better test scores, but the largest trial of the drug taken by mouth, in older stroke survivors, found no benefit, and South Korea’s regulator stopped recommending it after its own review. Short-term gains after head injury rest on low-quality studies, often with the drug given into a vein. In healthy people, the only data come from small studies of artificially induced memory problems or high-altitude exposure, and no study has looked at aging or lifespan. Brain-protection claims rest on animal and laboratory work.

Its safety record is reassuring in the short term: side effects in trials were mostly mild and close to placebo rates when taken by mouth. Because the kidneys clear it, reduced kidney function raises blood levels, and effects in pregnancy are unknown. Products bought online carry real risks of mislabeling and contamination.

Much of the early research was linked to the companies that developed the drug, and the Korean review was driven partly by the cost of paying for it. The overall evidence is old, inconsistent and thin for the use most people now have in mind: sharper or longer-lasting cognition in a healthy brain.

Top - Benefits - Risks - Protocol